EML4 and lung carcinoma: In a recent study on ALK FISH-positive lung cancer, patients with canonical fusion partners involving EML4 were found to have better overall survival (20.6 months vs. 5.4 months, p < 0.01) than those with noncanonical ALK fusions [18].